Study Leaves Transvaginal Mesh Controversy at Impasse
Transvaginal mesh proved noninferior to native tissue repair for vaginal prolapse but missed the superiority target in an FDA-mandated, postmarket, prospective parallel-cohort study. The 36-month composite treatment success rates were 89.3% with mesh repair and 80.2% with native tissue repair, falling within the prespecified 12% margin for noninferiority but not achieving superiority. However, mesh demonstrated […]